Category: Policy / Pricing
PharmaSignal — Policy / Pricing
List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
Drug Channels
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .
EU invests 30m to fight antimicrobial resistance
Pharmaphorum
The EU has pledged 30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
BioSpace
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie’s deal with the White House to avoid tariffs.
Kennedy changes vaccine panel charter after legal setback
Pharmaphorum
A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
FDA floats new clinical trial reforms; Takeda punts Denali brain drug
BioPharma Dive
In its budget request, the agency proposed a way to speed up early drug testing and help smaller biotech firms.
Trump revives pharma tariffs with 100% charges, but leaves loopholes
BioPharma Dive
Section 232 national security levies won’t apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.
US pharma tariffs of up to 100% finalised by Trump
Pharmaphorum
Trump signs his pharma tariffs executive order, which won’t affect most large pharma groups but could deal a hefty blow to smaller companies.
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
BioSpace
While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waiv
Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
BioSpace
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore re
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
BioSpace
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S.
Threat of Trump’s pharma tariffs looms again
Pharmaphorum
The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma
BioPharma Dive
A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.